The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| CARDIFF ONCOLOGY INC | COM | 14147L108 | 25,793 | 2,785,410 | SH | SOLE | 2,785,410 | 0 | 0 | ||
| CUE BIOPHARMA INC | COM | 22978P106 | 31,098 | 2,549,031 | SH | SOLE | 2,549,031 | 0 | 0 | ||
| DIAMEDICA THERAPEUTICS INC | COM NEW | 25253X207 | 7,963 | 870,228 | SH | SOLE | 870,228 | 0 | 0 | ||
| EYEPOINT PHARMACEUTICALS INC | COM NEW | 30233G209 | 2,032 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| FACEBOOK INC | CL A | 30303M102 | 14,727 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| LANTERN PHARMA INC | COM | 51654W101 | 12,948 | 713,806 | SH | SOLE | 713,806 | 0 | 0 | ||
| MAXAR TECHNOLOGIES INC | COM | 57778K105 | 100,223 | 2,650,000 | SH | SOLE | 2,650,000 | 0 | 0 | ||
| REPLIMUNE GROUP INC | COM | 76029N106 | 32,798 | 1,075,000 | SH | SOLE | 1,075,000 | 0 | 0 | ||
| TELEDYNE TECHNOLOGIES INC | COM | 879360105 | 22,751 | 55,000 | SH | SOLE | 55,000 | 0 | 0 | ||
| TFF PHARMACEUTICALS INC | COM | 87241J104 | 21,246 | 1,565,682 | SH | SOLE | 1,565,682 | 0 | 0 | ||